False Claims Act suit alleging that medical practices engaged in a scheme to overbill Medicare for Amgen Inc. drugs is now dismissed, a New York federal district court said.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...
In a report released today, Michael Yee from Jefferies assigned a Buy rating to Amgen (AMGN – Research Report), with a price target of ...
Amgen will test its obesity drug candidate in patients at risk of weight-related conditions such as heart, liver and kidney ...
An academic partnership to improve diversity in clinical trials has drafted its first industry team members. | An academic ...
Oppenheimer analyst Jay Olson maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $380.00. The ...
With a sold-out crowd and a ton of momentum, Rory McIlroy appeared poised to post his first DP World Tour victory on Northern ...
We came across a bullish thesis on Amgen Inc. (AMGN) on Disruptive analytics’ Substack by Magnus Ofstad. In this article we ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback